Association of Urinary Pentosidine Levels With the Risk of Fractures in Patients With Severe Osteoporosis: The Japanese Osteoporosis Intervention Trial‐05 (JOINT‐05)
Authors:
- Shiro TanakaSTShiro Tanaka
- Mitsuru SaitoMSMitsuru Saito
- Hiroshi HaginoHHHiroshi Hagino
- Satoshi MoriSMSatoshi Mori
- Toshitaka NakamuraTNToshitaka Nakamura
- Hiroaki OhtaHOHiroaki Ohta
- Teruki SoneTSTeruki Sone
- Toshitsugu SugimotoTSToshitsugu Sugimoto
- Satoshi SoenSSSatoshi Soen
- Adequate Treatment of Osteoporosis (A‐TOP) Research GroupAGAdequate Treatment of Osteoporosis (A‐TOP) Research Group
Open Access
- 31 August 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 6 (10) , e10673
Abstract
Associations between urinary pentosidine, one of the advanced glycation end products in collagen, and the risk of fracture in patients with severe osteoporosis are unknown. In this study, we investigated whether the urinary pentosidine level is associated with the incidence of morphometric vertebral fracture and nonvertebral fracture using data of a randomized, controlled trial, JOINT‐05. JOINT‐05 enrolled Japanese women aged 75 years or older with primary osteoporosis. Patients were randomly assigned (1:1) to receive sequential therapy (teriparatide followed by alendronate) or monotherapy with alendronate for 120 weeks. Incidences of vertebral and nonvertebral fractures were assessed morphologically. During treatment, urinary levels of pentosidine and serum levels of bone turnover markers (osteocalcin, procollagen type I amino‐terminal propeptide, and tartrate‐resistant acid phosphatase 5b) were measured. A total of 967 patients with baseline pentosidine levels were included in the study. Of these, 137 had vertebral fractures, and 42 had nonvertebral fractures. The rate ratios for vertebral fracture for the second (30–39 pmol/mL), third (40–49 pmol/mL), and fourth quartile (≥50 pmol/mL) groups divided by pentosidine level compared with the first quartile (p = 0.06), 1.51 (95% CI 0.87–2.61, p = 0.14), and 1.69 (95% CI 1.01–2.83, p = 0.05), respectively. The corresponding rate ratios for nonvertebral fracture were 3.07 (95% CI 0.88–10.70, p = 0.08), 2.34 (95% CI 0.61–8.95, p = 0.22), and 3.95 (95% CI 1.14–13.67, p = 0.03), respectively. The association of the urinary pentosidine level with the incidence of nonvertebral fracture was the strongest among the biomarkers assessed in the study. In conclusion, the urinary pentosidine level was associated with the risk of fracture in patients with severe osteoporosis receiving teriparatide or alendronate. © 2022 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.Keywords
Funding Information
- Asahi Kasei Therapeutics Corporation
This publication has 25 references indexed in Scilit:
- Urinary pentosidine improves risk classification using fracture risk assessment tools for postmenopausal womenJournal of Bone and Mineral Research, 2011
- The Fracture and Immobilization Score (FRISC) for risk assessment of osteoporotic fracture and immobilization in postmenopausal women―A joint analysis of the Nagano, Miyama, and Taiji CohortsBone, 2010
- Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis patients under bisphosphonate treatmentJournal of Bone and Mineral Metabolism, 2010
- Pentosidine and Increased Fracture Risk in Older Adults with Type 2 DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2009
- Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX™)Osteoporosis International, 2008
- Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fracturesJournal of Bone and Mineral Metabolism, 2008
- Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebraeBone, 2006
- Extracellular post-translational modifications of collagen are major determinants of biomechanical properties of fetal bovine cortical boneBone, 2006
- Relationship Between Changes in Biochemical Markers of Bone Turnover and BMD to Predict Vertebral Fracture RiskJournal of Bone and Mineral Research, 2004
- Vertebral fracture assessment using a semiquantitative techniqueJournal of Bone and Mineral Research, 1993